JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more
JW Pharmaceutical Corp (001065) - Total Liabilities
Latest total liabilities as of September 2025: ₩257.46 Billion KRW
Based on the latest financial reports, JW Pharmaceutical Corp (001065) has total liabilities worth ₩257.46 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
JW Pharmaceutical Corp - Total Liabilities Trend (2014–2024)
This chart illustrates how JW Pharmaceutical Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
JW Pharmaceutical Corp Competitors by Total Liabilities
The table below lists competitors of JW Pharmaceutical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Radiant Logistics Inc
NYSE MKT:RLGT
|
USA | $218.17 Million |
|
Puma Biotechnology Inc
NASDAQ:PBYI
|
USA | $85.96 Million |
|
FS Bancorp Inc
NASDAQ:FSBW
|
USA | $2.89 Billion |
|
Senvest Capital Inc
PINK:SVCTF
|
USA | $4.19 Billion |
|
MCNEX Co. Ltd
KQ:097520
|
Korea | ₩221.01 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥222.24 Million |
|
Funding Circle Holdings plc
PINK:FDCHF
|
USA | $307.45 Million |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
USA | $44.48 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down JW Pharmaceutical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JW Pharmaceutical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual total liabilities of JW Pharmaceutical Corp from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩275.11 Billion | -27.53% |
| 2023-12-31 | ₩379.60 Billion | -5.62% |
| 2022-12-31 | ₩402.21 Billion | -9.52% |
| 2021-12-31 | ₩444.51 Billion | +30.12% |
| 2020-12-31 | ₩341.62 Billion | -0.44% |
| 2019-12-31 | ₩343.12 Billion | +2.83% |
| 2018-12-31 | ₩333.68 Billion | -7.34% |
| 2017-12-31 | ₩360.10 Billion | -3.91% |
| 2016-12-31 | ₩374.76 Billion | -3.43% |
| 2015-12-31 | ₩388.07 Billion | +5.11% |
| 2014-12-31 | ₩369.22 Billion | -- |